Articles

Keep up with our latest news and industry insights
by exploring the articles section

Polpharma Group's environmental responsibility

In the last couple of years, we conducted a variety of initiatives and programmes aimed at making our business more sustainable.

Rising Prevalence of Cancer and Its Impact on the HP API Market

An inside look into the growing demand for HPAPIs in oncology

An Overview of Breast Cancer: Understanding Risks, Treatments, and Market Trends

Polpharma's HP API facility is live!

On September 18th, we launched the new state-of-the-art manufacturing facility.

Addressing Nitrosamine Risks in Pharmaceutical Manufacturing

Get a behind-the-scenes look into how we deal with Nitrosamines control.

A Comprehensive Overview and Prognosis of the Diabetes Market

Read about diabetes types, methods of treatment and market overview.

Tackling the Dynamic Challenge of N-nitrosamines Control with High Performance Analytical Instrumentation

We partnered with Waters, , a leading provider of lab equipment, to address the issue of Nitrosamines.

First CADIFA certification from ANVISA for Etodolac

We're proud to announce the milestone of our presence on the LATAM market.

KiloLab Laboratory: strategic milestone achieved!

KiloLab Laboratory - a development and production in a kilogram scale - has been launched at Polpharma API.

Ryvu Therapeutics and Polpharma sign two agreements in the area of RVU120 active substance (API) production for Phase II clinical trials

Polpharma API takes on a CDMO project for Ryvu Therapeutics.

Cryogenic infrastructure at API facility

New installation at Polpharma provides the best quality of products

Liophilization: What does a strawberry have in common with Polpharma API?

On November 2022, at Polpharma API Plant, we implemented freeze-drying machine!

Polpharma’s strategic investment in HP API facility, the first of this kind in Poland

We are making a strategic investment in a HPAPI facility, which will make Poland a strong pillar of the European pharmaceutical industry.

Safe approach in delivering nitrosamine-free API products

Karina Boszko, head of API Regulatory Affairs and Customer Technical Support Department, explains how we undertake this challenge.

Polpharma partners with Pikralida biopharmaceutical start-up

Polpharma has established cooperation with Pikralida, a biopharmaceutical start-up that is working on a breakthrough therapeutic solution

September 2019 was the date when the transformation process started in the API Business Unit of Polpharma.

Learn about the transformation process at Polpharma API, including how we use KPIs to facilitate rapid and correct decisions.

Searching for new, better, and innovative solutions. Digital Transformation at Polpharma API.

Learn about how digital transformation is impacting Polpharma API and the people who power it.

Polpharma API completed step 1. Risk Evaluation according to EMA’s request concerning presence of nitrosamines in drug products.

EMA’s CHMP requested on, that MAHs review human medicines with chemically synthesized APIs for the possible presence of nitrosamines.

Why particles size is important in pharmaceutical industry? Is it really problematic?

Learn about the importance of particles size in the pharmaceutical industry and how to control it.

Have a question?

Our specialists will be happy to guide you through our cooperation process.